 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| Venclexta (venetoclax) / Roche, AbbVie, 6MW3211 / Mabwell (Shanghai) Biosci
Enrollment open, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS (clinicaltrials.gov) - Mar 15, 2023
P1/2, N=120, Recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=30 --> 120 | Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Jul 2023 --> Jun 2024
- | 6MW3211 / Mabwell (Shanghai) Biosci
Journal, Checkpoint inhibition: Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment. (Pubmed Central) - Jan 4, 2023
In addition, multiplex fluorescent immunohistochemistry (mIHC) staining shows that PD-L1 and CD47 co-express on several different types of human tumor tissues. These results support the development of 6MW3211 for the treatment of PD-L1 and CD47 double positive cancers.
- || 6MW3211 / Mabwell (Shanghai) Biosci
New P1 trial: A Clinical Study of 6MW3211 Injection to Treat Relapsed/Refractory AML or MDS (clinicaltrials.gov) - Jul 7, 2022
P1, N=30, Not yet recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- || 6MW3211 / Mabwell (Shanghai) Biosci
New P2 trial: A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma (clinicaltrials.gov) - Jul 7, 2022
P2, N=40, Not yet recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- || 6MW3211 / Mabwell (Shanghai) Biosci
New P2 trial, Metastases: A Clinical Study of 6MW3211 in Patients With Renal Cancer (clinicaltrials.gov) - Jun 30, 2022
P2, N=30, Not yet recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- || 6MW3211 / Mabwell (Shanghai) Biosci
New P2a trial, Metastases: A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer (clinicaltrials.gov) - Jun 23, 2022
P2a, N=36, Not yet recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- |||| 6MW3211 / Mabwell (Shanghai) Biosci
Enrollment open, Metastases: A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm (clinicaltrials.gov) - May 9, 2022
P1/2, N=272, Recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
These results support the development of 6MW3211 for the treatment of PD-L1 and CD47 double positive cancers. Not yet recruiting --> Recruiting
- ||||| 6MW3211 / Mabwell (Shanghai) Biosci
New P1/2 trial, Metastases: A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm (clinicaltrials.gov) - Sep 17, 2021
P1/2, N=272, Not yet recruiting, Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.